Changes in plasma copeptin levels during hemodialysis: Are the physiological stimuli active in hemodialysis patients?

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Ettema, Esmée M ^a   Kuipers, Johanna ^b   Assa, Solmaz ^a   Bakker, Stephan J L ^a   Groen, Henk ^a   Westerhuis, Ralf ^b   Gaillard, Carlo A J M ^a   Gansevoort, Ron T ^a   Franssen, Casper F M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b Dialysis Center Groningen   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; COPEPTIN; SODIUM; BRAIN NATRIURETIC PEPTIDE; GLYCOPEPTIDE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ADULT; AGE; ARTICLE; ARTIFICIAL KIDNEY; BLOOD VOLUME; BODY WEIGHT; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HORMONE BLOOD LEVEL; HORMONE RELEASE; HUMAN; HYPERTENSION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MIDDLE AGED; OBSERVATIONAL STUDY; PLASMA OSMOLALITY; SEX; SODIUM BLOOD LEVEL; AGED; BLOOD; BLOOD PRESSURE; OSMOLARITY;

AGED; BLOOD PRESSURE; BLOOD VOLUME; FEMALE; GLYCOPEPTIDES; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; OSMOLAR CONCENTRATION; PEPTIDE FRAGMENTS; RENAL DIALYSIS; SODIUM;

EID: 84929377781     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0127116     Document Type: Article

References (30)

1. Yamada K, Nakayama M, Miura Y, Nakano H, Mimura N, Yoshida S. Role of AVP in the regulation of vascular tonus and blood pressure in patients with chronic renal failure. Regul Pept 1993 Apr 29; 45(1- 2:91-95. PMID: 8394594
2. Nakayama M, Yamada K, Nakano H, Miura Y, Tuchida H, Kawaguchi Y. Stimulated secretion of arginine vasopressin during hemodialysis in patients with hemodialysis hypotension. Nephron 1998 Aug; 79(4):488-489. PMID: 9689174
3. Martinez-Vea A, Botey A, Montoliu I, Lopez Pedret J, Revert L. Vasopressin response in hemodialysis patients. Clin Nephrol 1985 Dec; 24(6):316. PMID: 4075603
4. Iitake K, Kimura T, Matsui K, Ota K, Shoji M, Inoue M, et al. Effect of haemodialysis on plasma ADH levels, plasma renin activity and plasma aldosterone levels in patients with end-stage renal disease. Acta Endocrinol (Copenh) 1985 Oct; 110(2):207-213. PMID: 3904290
5. Zoccali C, Mallamaci F, Ciccarelli M, Parlongo S, Salnitro F, Curatola A. The reflex control of vasopressin in haemodialysis patients. Nephrol Dial Transplant 1991; 6(9):631-636. PMID: 1745386
6. Cernaro V, Lacquaniti A, Lorenzano G, Loddo S, Romeo A, Donato V, et al. Apelin, plasmatic osmolality and hypotension in dialyzed patients. Blood Purif 2012; 33(4):317-323. doi: 10.1159/000337104 PMID: 22699819
7. Ettema EM, Zittema D, Kuipers J, Gansevoort RT, Vart P, de Jong PE, et al. Dialysis hypotension: a role for inadequate increase in arginine vasopressin levels? A systematic literature review and metaanalysis. Am J Nephrol 2014; 39(2):100-109. doi: 10.1159/000358203 PMID: 24503523
8. van der Zee S, Thompson A, Zimmerman R, Lin J, Huan Y, Braskett M, et al. Vasopressin administration facilitates fluid removal during hemodialysis. Kidney Int 2007 Feb; 71(4):318-324. PMID: 17003815
9. Morgenthaler NG, Struck J, Jochberger S, Dunser MW. Copeptin: clinical use of a new biomarker. Trends Endocrinol Metab 2008 Mar; 19(2):43-49. doi: 10.1016/j.tem.2007.11.001 PMID: 18291667
10. Morgenthaler NG. Copeptin: a biomarker of cardiovascular and renal function. Congest Heart Fail 2010 Jul; 16 Suppl 1:S37-44. doi: 10.1111/j.1751-7133.2010.00177.x PMID: 20653710
11. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 2006 Jan; 52(1):112-119. PMID: 16269513
12. Dabla PK, Dabla V, Arora S. Co-peptin: Role as a novel biomarker in clinical practice. Clin Chim Acta 2011 Jan 14; 412(1-2):22-28.
13. Balanescu S, Kopp P, Gaskill MB, Morgenthaler NG, Schindler C, Rutishauser J. Correlation of plasma copeptin and vasopressin concentrations in hypo-, iso-, and hyperosmolar States. J Clin Endocrinol Metab 2011 Apr; 96(4):1046-1052. doi: 10.1210/jc.2010-2499 PMID: 21289257
14. Fenske W, Wanner C, Allolio B, Drechsler C, Blouin K, Lilienthal J, et al. Copeptin levels associate with cardiovascular events in patients with ESRD and type 2 diabetes mellitus. J Am Soc Nephrol 2011 Apr; 22(4):782-790. doi: 10.1681/ASN.2010070691 PMID: 21415158
15. Li X, Yang XC, Sun QM, Chen XD, Li YC. Brain natriuretic peptide and copeptin levels are associated with cardiovascular disease in patients with chronic kidney disease. Chin Med J (Engl) 2013 Mar; 126 (5):823-827. PMID: 23489784
16. Artunc F, Nowak A, Mueller C, Breidthardt T, Twerenbold R, Wagner R, et al. Plasma concentrations of the vasoactive peptide fragments mid-regional pro-adrenomedullin, C-terminal pro-endothelin 1 and copeptin in hemodialysis patients: associated factors and prediction of mortality. PLoS One 2014 Jan 22; 9(1):e86148. doi: 10.1371/journal.pone.0086148 PMID: 24465926
17. Assa S, Hummel YM, Voors AA, Kuipers J, Westerhuis R, de Jong PE, et al. Hemodialysis-induced regional left ventricular systolic dysfunction: prevalence, patient and dialysis treatment-related factors, and prognostic significance. Clin J Am Soc Nephrol 2012 Oct; 7(10):1615-1623. doi: 10.2215/CJN.00850112 PMID: 22822014
18. Struck J, Morgenthaler NG, Bergmann A. Copeptin, a stable peptide derived from the vasopressin precursor, is elevated in serum of sepsis patients. Peptides 2005 Dec; 26(12):2500-2504. PMID: 15922490
19. Sauerbrei W. The use of resampling methods to simplify regression models in medical statistics. Journal of the Royal Statistical Society: Series C (Applied Statistics) 1999; 48(3):313-329.
20. Schneditz D, Putz-Bankuti C, Ribitsch W, Schilcher G. Correction of plasma concentrations for effects of hemoconcentration or hemodilution. ASAIO J 2012 Mar-Apr; 58(2):160-162. doi: 10.1097/MAT.0b013e318243660f PMID: 22370687
21. Bhandari SS, Loke I, Davies JE, Squire IB, Struck J, Ng LL. Gender and renal function influence plasma levels of copeptin in healthy individuals. Clin Sci (Lond) 2009 Feb; 116(3):257-263. doi: 10.1042/CS20080140 PMID: 18647134
22. Shoji T, Tsubakihara Y, Fujii M, Imai E. Hemodialysis-associated hypotension as an independent risk factor for two-year mortality in hemodialysis patients. Kidney Int 2004 Sep; 66(3):1212-1220. PMID: 15327420
23. Park J, Rhee CM, Sim JJ, Kim YL, Ricks J, Streja E, et al. A comparative effectiveness research study of the change in blood pressure during hemodialysis treatment and survival. Kidney Int 2013 Oct; 84 (4):795-802. doi: 10.1038/ki.2013.237 PMID: 23783241
24. Flythe JE, Kimmel SE, Brunelli SM. Rapid fluid removal during dialysis is associated with cardiovascular morbidity and mortality. Kidney Int 2011 Jan; 79(2):250-257. doi: 10.1038/ki.2010.383 PMID: 20927040
25. Ronco C, Bowry S. Nanoscale modulation of the pore dimensions, size distribution and structure of a new polysulfone-based high-flux dialysis membrane. Int J Artif Organs 2001 Oct; 24(10):726-735. PMID: 11817320
26. Santoro A. Infusing vasopressin to prevent intradialytic hypotension. Nat Clin Pract Nephrol 2007 Jul; 3 (7):362-363. PMID: 17502885
27. Mutlu GM, Factor P. Role of vasopressin in the management of septic shock. Intensive Care Med 2004 Jul; 30(7):1276-1291. PMID: 15103461
28. Nord E, Danovitch GM. Vasopressin response in haemodialysis patients. Proc Eur Dial Transplant Assoc 1979; 16:238-243. PMID: 398493
29. Barrett LK, Singer M, Clapp LH. Vasopressin: mechanisms of action on the vasculature in health and in septic shock. Crit Care Med 2007 Jan; 35(1):33-40. PMID: 17133186
30. Sharman A, Low J. Vasopressin and its role in critical care. Contin Educ Anaesth Crit Care Pain 2008; 8(4):134-137.